BioCentury
ARTICLE | Finance

No deal for Anthera

March 1, 2010 8:00 AM UTC

Pulmonary and inflammation company Anthera Pharmaceuticals Inc. planned to price its IPO last week but didn't make it out.

Instead, the company twice lowered its price while increasing the number of shares. On Wednesday, it dropped to $8-$9 from $13-$15 and boosted the shares to 5.5 million from 4.6 million. Then on Friday, it lowered its price to $7 and raised the shares to 6 million...